» Articles » PMID: 19789347

An A13 Repeat Within the 3'-untranslated Region of Epidermal Growth Factor Receptor (EGFR) is Frequently Mutated in Microsatellite Instability Colon Cancers and is Associated with Increased EGFR Expression

Abstract

Colorectal cancers (CRC) with microsatellite instability (MSI) have clinical, pathologic, genetic, and epigenetic features distinct from microsatellite-stable CRC. Examination of epidermal growth factor receptor (EGFR) mRNA and protein expression levels in a panel of colon cancer cell lines identified strong expression of EGFR in multiple cell lines with MSI. Although no relationship between EGFR overexpression and the length of a CA dinucleotide repeat in intron 1 was observed, a variant A13/A14 repeat sequence within the 3'-untranslated region (3'-UTR) of the EGFR gene was identified, which was mutated by either mononucleotide or dinucleotide adenosine deletions in 64% of MSI cell lines and 69% of MSI colon tumors. Using a Tet-Off system, we show that this mutation increases EGFR mRNA stability in colon cancer cells, providing a mechanistic basis for EGFR overexpression in MSI colon cancer cell lines. To determine whether this mutation is a driver or a bystander event in MSI colon cancer, we examined the effect of pharmacologic and molecular inhibition of EGFR in EGFR 3'-UTR mutant MSI cell lines. Cell lines with an EGFR 3'-UTR mutation and that were wild-type (WT) for downstream signaling mediators in the Ras/BRAF and PIK3CA/PTEN pathways were sensitive to EGFR inhibition, whereas those harboring mutations in these signaling mediators were not. Furthermore, in cell lines WT for downstream signaling mediators, those with EGFR 3'-UTR mutations were more sensitive to EGFR inhibition than EGFR 3'-UTR WT cells, suggesting that this mutation provides a growth advantage to this subset of MSI colon tumors.

Citing Articles

CYpHER: catalytic extracellular targeted protein degradation with high potency and durable effect.

Crook Z, Sevilla G, Young P, Girard E, Phi T, Howard M Nat Commun. 2024; 15(1):8731.

PMID: 39384759 PMC: 11464628. DOI: 10.1038/s41467-024-52975-2.


Detecting microsatellite instability by length comparison of microsatellites in the 3' untranslated region with RNA-seq.

Choi J, Lee J, Lee S Brief Bioinform. 2024; 25(5).

PMID: 39210504 PMC: 11361843. DOI: 10.1093/bib/bbae423.


Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair.

Ooki A, Osumi H, Yoshino K, Yamaguchi K Gastric Cancer. 2024; 27(5):907-931.

PMID: 38922524 PMC: 11335850. DOI: 10.1007/s10120-024-01523-4.


Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3' untranslated region mutations.

Schuster S, Arora S, Wladyka C, Itagi P, Corey L, Young D Cell Rep. 2023; 42(8):112840.

PMID: 37516102 PMC: 10540565. DOI: 10.1016/j.celrep.2023.112840.


Epidermal growth factor receptor intron 1 polymorphism and microsatellite instability in sporadic colorectal cancer.

Marinovic S, Vukovic K, Skrtic A, Poljak M, Petek S, Petek L Oncol Lett. 2021; 21(2):131.

PMID: 33552252 PMC: 7798105. DOI: 10.3892/ol.2020.12392.


References
1.
Nagahara H, Mimori K, Ohta M, Utsunomiya T, Inoue H, Barnard G . Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res. 2005; 11(4):1368-71. DOI: 10.1158/1078-0432.CCR-04-1894. View

2.
Toyota M, Ahuja N, Herman J, Baylin S, Issa J . CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96(15):8681-6. PMC: 17576. DOI: 10.1073/pnas.96.15.8681. View

3.
Goel A, Nagasaka T, Arnold C, Inoue T, Hamilton C, Niedzwiecki D . The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2006; 132(1):127-38. DOI: 10.1053/j.gastro.2006.09.018. View

4.
Weihua Z, Tsan R, Huang W, Wu Q, Chiu C, Fidler I . Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 2008; 13(5):385-93. PMC: 2413063. DOI: 10.1016/j.ccr.2008.03.015. View

5.
Hegde S, Sun W, Lynch J . Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol. 2008; 2(1):135-49. DOI: 10.1586/17474124.2.1.135. View